Kaken has rights to develop and commercialize sofpironium bromide in South Korea, China, and certain other Asian countries, but of course BOT will receive healthy royalties from them.
BOT themselves will be able to directly supply the rest of the world, with various country licensings.
BOT - Anything but charting, page-8727
-
- There are more pages in this discussion • 2,485 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.020(5.41%) |
Mkt cap ! $663.3M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $1.679M | 4.712M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 723246 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 158420 | 8 |
View Market Depth
| Last trade - 12.59pm 15/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |